PubRank

Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy

Clinical Trial ID NCT01029366

PubWeight™ 69.61‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01029366

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 18.99
2 T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011 12.58
3 Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014 8.21
4 The basic principles of chimeric antigen receptor design. Cancer Discov 2013 3.28
5 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
6 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
7 Chimeric antigen receptor therapy for cancer. Annu Rev Med 2013 1.94
8 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
9 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
10 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
11 The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012 1.37
12 Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol 2011 1.17
13 Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 2013 1.14
14 Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010 0.99
15 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
16 CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 2015 0.95
17 The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2012 0.88
18 Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 2016 0.87
19 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
20 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
21 Immunotherapy for pediatric leukemia. Front Oncol 2013 0.84
22 Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015 0.84
23 Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012 0.84
24 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
25 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
26 Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011 0.78
27 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
28 Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Hematol Oncol Clin North Am 2013 0.76
29 Toward synthetic biology with engineered T cells: a long journey just begun. Hum Gene Ther 2014 0.75
30 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100